




B-1574  
PATENT  
Docket No. 740481-42 1b 14

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of: )  
Robert M. LORENCE et al ) Group Art Unit:  
Serial No. 10/700,143 ) Examiner:  
Filed: November 3, 2003 )  
For: TREATING CARCINOID NEOPLASMS )  
WITH THERAPEUTIC VIRUSES )

**CERTIFICATE OF MAILING OR TRANSMISSION**  
[37 CFR 1.8(a)]

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage for First Class Mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450, on November 8, 2004.

Signature: 

Name: Stuart J. Friedman

**SUBMISSION UNDER 37 CFR 1.99**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

11/10/2004 SDENBOB1 00000076 10700143

01 FC:1806  
02 FC:1460

180.00 OP  
130.00 OP

Sir:

The following publications are submitted for consideration by the Patent and Trademark Office in connection with the above-captioned application:

Attenuated Veterinary Virus Vaccines for the Treatment of Colorectal Cancer, as Biological Response Modifiers; L. K. Csاتáry et al; 2d International Conference on Gastrointestinal Cancer; August 27-September 1, 1989.

Treatment of Malignant Tumors with Attenuated Newcastle Disease Virus Vaccine (Phase II Trial); L. Csاتáry et al; Update in Medicine, Surgery and Basic Science 1992; October 25-October 30, 1992.

Attenuated Veterinary Virus Vaccine for the Treatment of Cancer; Laszlo K. Csatary et al; *Cancer Detection and Prevention*, 17(6): 619-627 (1993)


Use of Newcastle Disease Virus Vaccine (NMTH-68/H) in a Patient With High-Grade Glioblastoma; *JAMA*, Volume 281; May 5, 1999

Beneficial Treatment of Patients with Advanced Cancer Using a Newcastle Disease Virus Vaccine (MTH-68/H); Laszlo K. Csatary et al; *Anticancer Research* 19: 635-638 (1999)

Induction of Apoptosis by a Newcastle Disease Virus Vaccine (MTH-68/H) in PC12 Rat Phaeochromocytoma Cells; Z. Fabian et al; *Anticancer Research* 21: 125-136 (2001)

Pursuant to 37 CFR 1.99 (b)(1) submitter submits the fee (\$180.00) set forth in 37 CFR 1.17(p). Submitter notes that this submission is made more than two months after publication but prior to the mailing of a notice of allowance. The publications submitted herewith could not have been submitted earlier and, therefore, the processing fee set forth in 37 CFR 1.17(i) (\$130.00) is also enclosed for a total fee submission of \$310.00.

Respectfully submitted,

  
\_\_\_\_\_  
Stuart J. Friedman  
Registration No. 24,312

Law Offices of Stuart J. Friedman  
28930 Ridge Road  
Mt. Airy, MD 21771  
Telephone: (301) 829-1003  
Facsimile: (301) 829-4107



Docket No. 740481-42  
Page 3

Page 3

CERTIFICATE OF SERVICE

**10/15/2014**  
**TECH CENTER 100/200**

This is to certify that a copy of the foregoing SUBMISSION UNDER 37 CFR 1.99 was served upon the applicant in accordance with 37 CFR 1.248 by mailing this 8<sup>th</sup> day of November, 2004, via first class mail, postage prepaid, to:

Lewis J. Kreisler  
Legal Department  
Wellstat Biologics Corporation  
930 Clopper Road  
Gaithersburg, MD 20878

Stuart J. Friedman